Bli medlem
Bli medlem

Du är här


European Technology Platform on Nanomedicine : How will Nanomedicine revolutionize healthcare during the next 15 years?

| |
| |
| |
| |

How will Nanomedicine revolutionize healthcare during the next 15 years?

The new Strategic Research and Innovation Agenda (SRIA) of Nanomedicine is now

Paris, France, February 18, 2016 - European Technology Platform on
Nanomedicine (ETPN
) announces the publication of the new Strategic Research and Innovation
Agenda (SRIA) for Nanomedicine (available here: This
SRIA provides the ecosystem, including European, national and regional public
authorities, a concrete framework with roadmaps and priorities for research,
with a long term vision up to 2030, for the fruitful deployment of innovative
Nanomedicine solutions for healthcare.

Key recommendations of the SRIA update are:

1 Focus on unmet medical needs where only Nanomedicine can make the
difference by providing currently lacking diagnostic and therapeutic
2 Facilitate the matching of nanotechnology features with other Key Enabling
Technologies (KETs) for new smart and connected products and devices,
3 Optimize the implementation of medical innovations into the healthcare
systems by balancing benefits for patients with cost constrains and
industrial return on investment
4 improve competitiveness of European healthcare economy at the global market

The SRIA contains detailed recommendations for R&D topics on selected diseases
that affect a large number of patients (cardio-vascular diseases, cancer,
diabetes, neurodegenerative diseases, infection diseases, osteoarticular
pathologies and others). Moreover, the focus is set on translation of
research results, i.e. the capacity to move their lab proof of concept
towards an approved and certified product available for patients on the
healthcare market.

For the first time, the best Nanomedicine experts and scientists from the ETPN
and EuroNanoMed II have joined forces to design the new SRIA of Nanomedicine,
with the objective to reflect the future challenges that the European
Community will have to address. ETPN has recently celebrated its 10th
anniversary and this update of the SRIA reflects the tremendous advancements
and progress done since its inception for the global benefit of patients and
EU citizens.
The dissemination of the SRIA is supported by the European project
ENATRANS( part of its mission to raise awareness about
innovation in Nanomedicine.

The updated SRIA for Nanomedicine is now available and can be downloaded here:

About ETPN

The European Technology Platform Nanomedicine was established in 2005 as a
joint venture of the European Commission and CEOs of large industrial
companies, SMEs and academic research institutions to investigate and advance
joint activities in the area of nanotechnology in medicine. Since 2005 the
ETPN published a number of strategic documents outlining the needs and
roadmaps for nanomedicine research in Europe. The ETPN contributed to set up
numerous European funded projects providing a first impression of the
conditions for a suitable social and economic environment and the structural
requirements for an efficient translation of R&D results into innovative
nanomedicine. The ETPN supports its members in coordinating their joint
research efforts and improving communication amongst the members as well as
towards the European Commission and the European Member States.

In 2013, ETPN has published a White Paper "Contribution of Nanomedicine to
Horizon 2020
" setting the groundwork to manage the efficient translation of nanotechnology
from a Key Enabling Technology (KET) into new and innovative medical
products. Two years later the concrete implementation of the recommendations
formulated in this strategic document started with the launch of the
EU-Nano-Characterization Lab, of 3 pilot lines for GMP manufacturing of
nanomedicine and well as with the constitution of the Translation Advisory
Board in the framework of the ENATRANS Coordination and Support Action.

About EuroNanomed

EuroNanoMed II is an ERA-NET comprising 20 partners from 17 countries/regions,
that has been granted for funding through the European Commission 's 7th
Framework Programme. It will run from November 2012 to October 2016.
The ERA-NET serves as a platform for funding agencies and ministries, to
develop joint activities and programmes in order to coordinate high quality
research across national borders.
EuroNanoMed II builds on the achievements of its predecessor, the EuroNanoMed
ERA-NET, which was funded by the European Commission from 2009 to 2011.
Through 3 joint calls for proposals, EuroNanoMed granted 24 transnational
research projects on Nanomedicine with a total funding of €25 million from
its partner organizations and an additional €21 million from the
participating project partners.
The aim of EuroNanoMed II is to continue fostering the competitiveness of
European nanomedicine actors through the support of transnational
collaborative and multidisciplinary research and technology development
projects with participants ranging from academia, clinical/public health
communities, and industry (particularly small and medium-sized enterprises).
Among the most important activities of EuroNanoMed II are annually launched
joint transnational calls for proposals for research groups operating in the
EuroNanoMed II partner countries.


General Secretary of ETPN
Dr. Alexandre Ceccaldi
+33 1 40 794 324


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: European Technology Platform on Nanomedicine via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.